K&L Gates LLP has advised molecular diagnostics and life sciences company Nova Satra DX Pte Ltd (“NSDX”) in relation to a US$2 million investment and acquisition of a minority stake in the company by Malaysian conglomerate Genting Group.
Singapore-based NSDX works in collaboration with global centers of scientific excellence to research, develop and commercialize blood-based tests for cancer. The deal sees Genting Group acquiring an equity stake in NSDX, with the funds raised to be used for working capital, research & development and commercialization purposes.
Singapore partner Nicholas Hanna (picture) led the K&L Gates team on the deal, assisted by Singapore associate Mark Tan.
Law Firms: K&L Gates;
Clients: Nova Satra DX Pte Ltd;